{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:34:39Z","timestamp":1790652879495,"version":"4.1.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"\n Importance<\/jats:title>\n Clinical trials evaluating population-based screening tests or other interventions likely to affect care delivery in real-world settings often do not consider spillover effects, such as whether the intervention rollout affects access to limited health care services.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine whether regional participation in a population-based screening trial (NHS-Galleri) of a cell-free DNA\u2013based multicancer early detection (MCED) test was associated with changes in cancer diagnostic delay rates.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Cross-sectional study of all 21 cancer alliance regions in England, 8 of which participated in the population-based MCED screening trial. An event study using difference-in-differences design evaluated changes from 6 months before (April 2021) to 3 years after trial start (September 2024).<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Regional participation in the population-based MCED screening trial.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was diagnostic delay rates (percentage of patients referred for suspected cancer evaluation taking longer than 28 days to reach diagnostic resolution), a surrogate measure for system-level spillover effects; the secondary outcome was patient referral rates. Analysis focused on a primary group of 3 cancer types (head and neck, lung, and upper gastrointestinal) that were identified in the trial protocol and were not subject to routine screening.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Overall, 1\u202f875\u202f236 patient referrals for suspected head and neck, lung, or upper gastrointestinal cancers were recorded across all 21 regions. In the first 6 months of the population-based screening trial, diagnostic delay rates increased in participating regions (28.6% before trial start and 29.6% after) and decreased in nonparticipating regions (28.9% to 26.3%), an adjusted difference-in-differences estimate of 3.4 percentage points (95% CI, 1.9-5.0;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). This increase persisted during the second 6-month period (adjusted difference-in-differences estimate of 4.8 percentage points [95% CI, 1.9-7.7;\n P<\/jats:italic>\n \u2009=\u2009.003]) and was no longer statistically significant thereafter. Patient referral rates for suspected head and neck, lung, and upper gastrointestinal cancers were also higher in participating regions in the first 6 months (adjusted difference-in-differences estimate of 23.8 per 100\u202f000 population [95% CI, 0.9-46.8;\n P<\/jats:italic>\n \u2009=\u2009.04]).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Regional participation in a population-based MCED screening trial was associated with a modest increase in diagnostic delay rates for patients referred for suspected head and neck, lung, and upper gastrointestinal cancers. This increase is unlikely to have materially affected interpretation of the MCED screening trial primary findings. Future trials of population-based screening interventions likely to affect demand for limited health care resources should consider monitoring for system-level spillover effects.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.6803","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T23:30:15Z","timestamp":1780183815000},"page":"125","source":"Crossref","is-referenced-by-count":7,"title":["Cancer Diagnostic Delay Rates Associated With a Population-Based Screening Trial Evaluating a Cell-Free DNA Multicancer Early Detection Test"],"prefix":"10.1001","volume":"336","author":[{"given":"Sean","family":"Mann","sequence":"first","affiliation":[{"name":"RAND, Arlington, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Nascimento de Lima","sequence":"additional","affiliation":[{"name":"RAND, Arlington, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Eagan","sequence":"additional","affiliation":[{"name":"RAND, Arlington, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agne","family":"Ulyte","sequence":"additional","affiliation":[{"name":"RAND Europe, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth Ann","family":"Griffin","sequence":"additional","affiliation":[{"name":"RAND, Arlington, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"19","key":"joi260038r1","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.3390\/cancers14194818","article-title":"Cell-free DNA-based multi-cancer early detection test in an asymptomatic screening population (NHS-Galleri): design of a pragmatic, prospective randomised controlled trial.","volume":"14","author":"Neal","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"joi260038r2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s11524-007-9228-9","article-title":"The effect of patient navigation on time to diagnosis, anxiety, and satisfaction in urban minority women with abnormal mammograms: a randomized controlled trial.","volume":"85","author":"Ferrante","year":"2008","journal-title":"J Urban Health"},{"issue":"10","key":"joi260038r3","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1158\/1055-9965.EPI-12-0513","article-title":"Patient navigation improves cancer diagnostic resolution: an individually randomized clinical trial in an underserved population.","volume":"21","author":"Raich","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"31","key":"joi260038r4","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1200\/JCO.2015.61.1301","article-title":"Electronic trigger-based intervention to reduce delays in diagnostic evaluation for cancer: a cluster randomized controlled trial.","volume":"33","author":"Murphy","year":"2015","journal-title":"J Clin Oncol"},{"issue":"14","key":"joi260038r5","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/jama.2023.18755","article-title":"A multilevel primary care intervention to improve follow-up of overdue abnormal cancer screening test results: a cluster randomized clinical trial.","volume":"330","author":"Atlas","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"joi260038r6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3322\/caac.21457","article-title":"Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.","volume":"68","author":"Wolf","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"joi260038r7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.breast.2014.08.009","article-title":"ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).","volume":"23","author":"Cardoso","year":"2014","journal-title":"Breast"},{"issue":"1","key":"joi260038r9","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1186\/s13063-024-08675-9","article-title":"Negative spillover due to constraints on care delivery: a potential source of bias in pragmatic clinical trials.","volume":"25","author":"Mann","year":"2024","journal-title":"Trials"},{"issue":"2","key":"joi260038r10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.7861\/fhj.2022-0052","article-title":"Diagnostics: a major priority for the NHS.","volume":"9","author":"Richards","year":"2022","journal-title":"Future Healthc J"},{"issue":"12","key":"joi260038r11","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1038\/sj.bjc.6604089","article-title":"The UK colorectal cancer screening pilot: results of the second round of screening in England.","volume":"97","author":"Weller","year":"2007","journal-title":"Br J Cancer"},{"issue":"1","key":"joi260038r12","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000113","article-title":"Trends in wait time for colorectal cancer screening and diagnosis 2013-2016.","volume":"11","author":"Hubers","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"joi260038r13","doi-asserted-by":"publisher","first-page":"h2147","DOI":"10.1136\/bmj.h2147","article-title":"The PRECIS-2 tool: designing trials that are fit for purpose.","volume":"350","author":"Loudon","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"joi260038r15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1741-7015-8-18","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.","volume":"8","author":"Schulz","year":"2010","journal-title":"BMC Med"},{"issue":"1","key":"joi260038r16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.7326\/M17-0046","article-title":"CONSORT statement for randomized trials of nonpharmacologic treatments: a 2017 update and a CONSORT extension for nonpharmacologic trial abstracts.","volume":"167","author":"Boutron","year":"2017","journal-title":"Ann Intern Med"},{"key":"joi260038r17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073725","article-title":"CONSORT harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials.","volume":"381","author":"Junqueira","year":"2023","journal-title":"BMJ"},{"issue":"4","key":"joi260038r20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines 4: rating the quality of evidence\u2013study limitations (risk of bias).","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"joi260038r21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1470-2045(23)00277-2","article-title":"Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study.","volume":"24","author":"Nicholson","year":"2023","journal-title":"Lancet Oncol"},{"issue":"9","key":"joi260038r23","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.","volume":"32","author":"Klein","year":"2021","journal-title":"Ann Oncol"},{"key":"joi260038r32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1511816","article-title":"Clinical referral to the NHS following multi-cancer early detection test results from the NHS-Galleri trial.","volume":"15","author":"Lowenhoff","year":"2025","journal-title":"Front Oncol"},{"key":"joi260038r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103733","article-title":"Experience of NHS diagnostic investigation following a multi-cancer early detection (MCED) screening test: qualitative interviews with NHS-Galleri trial participants who had a cancer signal detected.","volume":"91","author":"Marlow","year":"2026","journal-title":"EClinicalMedicine"},{"issue":"10409","key":"joi260038r34","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","article-title":"Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study.","volume":"402","author":"Schrag","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"joi260038r36","first-page":"75","article-title":"Reducing wait times through operations research: optimizing the use of surge capacity.","volume":"3","author":"Patrick","year":"2008","journal-title":"Healthc Policy"},{"key":"joi260038r18","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 63 (updated February 2022)","author":"Higgins","year":"2022"},{"key":"joi260038r35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-0-387-33636-7_10","volume-title":"Patient Flow: Reducing Delay in Healthcare Delivery","author":"Green","year":"2006"},{"key":"joi260038r8","unstructured":"Department of Veterans Affairs VHA. VHA Directive 1015: Colorectal Cancer Screening. Published April 3, 2020. Accessed February 26, 2024. https:\/\/www.va.gov\/vhapublications\/ViewPublication.asp?pub_ID=8815"},{"key":"joi260038r14","unstructured":"Heagerty? P. Experimental designs and randomization schemes: rethinking clinical trials: a living textbook of pragmatic clinical trials. Published 2023. Accessed November 5, 2024. https:\/\/rethinkingclinicaltrials.org\/chapters\/design\/experimental-designs-and-randomization-schemes\/experimental-designs-introduction\/"},{"key":"joi260038r19","unstructured":"US Preventive Services Task Force. Appendix VI: criteria for assessing internal validity of individual studies. Accessed August 22, 2023. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/about-uspstf\/methods-and-processes\/procedure-manual\/procedure-manual-appendix-vi-criteria-assessing-internal-validity-individual-studies"},{"key":"joi260038r22","unstructured":"NHS England. Cancer Waiting Times: National Time Series\u2014provider based, October 2009 to September 2023. Published 2023. Accessed May 24, 2024. https:\/\/www.england.nhs.uk\/statistics\/wp-content\/uploads\/sites\/2\/2024\/01\/Cancer-Waiting-Times-National-Time-Series-Oct-2009-Sep-2023-with-Revisions.xlsx"},{"key":"joi260038r24","unstructured":"NHS England. Monthly provider-based data and summaries. Accessed July 22, 2025. https:\/\/www.england.nhs.uk\/statistics\/statistical-work-areas\/cancer-waiting-times\/historic-cwt-data-before-september-2023\/monthly-prov-cwt\/"},{"key":"joi260038r25","unstructured":"NHS England. NHS workforce statistics. Published April 25, 2024. Accessed July 22, 2025. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/nhs-workforce-statistics\/january-2024"},{"key":"joi260038r26","unstructured":"NHS England. COVID-19 hospital activity. Accessed July 22, 2025. https:\/\/www.england.nhs.uk\/statistics\/statistical-work-areas\/covid-19-hospital-activity\/"},{"key":"joi260038r27","unstructured":"NHS England. Attribution from A&E providers to ICBs. Published 2024. Accessed May 16, 2024. https:\/\/www.england.nhs.uk\/statistics\/wp-content\/uploads\/sites\/2\/2023\/02\/Trust-ICB-Attribution-File.xls"},{"key":"joi260038r28","unstructured":"NHS National Cancer Patient Experience Survey. 2022 ICB to Alliance mapping document. Accessed May 16, 2024, 2024. https:\/\/www.ncpes.co.uk\/wp-content\/uploads\/2023\/07\/Sub-ICB-to-Alliance-mapping-2022_v1.4.csv"},{"key":"joi260038r29","unstructured":"NHS. NHS cancer programme: faster diagnosis framework. Published November 28, 2022. Accessed July 13, 2024. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2019\/07\/B1332-NHS-Cancer-Programme-Faster-Diagnosis-Framework-v5.pdf"},{"key":"joi260038r30","unstructured":"NHS England. National cancer waiting times monitoring dataset guidance, version 12.0. Published 2023. Accessed July 13, 2024. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2023\/08\/PRN00654-national-cancer-waiting-times-monitoring-dataset-guidance-v12.pdf"},{"key":"joi260038r31","unstructured":"NHS England. Cancer Prevalence Statistics England, 2020. 2023. Accessed July 22, 2024. https:\/\/github.com\/RANDCorporation\/mced-spillover-2025\/blob\/main\/data\/raw_covariates\/Cancer%2BPrevalence%2BStatistics%2BEngland%2B2020_download.xlsx"},{"key":"joi260038r37","unstructured":"Landmark NHS-Galleri trial demonstrates a substantial reduction in stage IV cancer diagnoses, increased stage I and II detection of deadly cancers, and four-fold higher cancer detection rate. Published February 19, 2026. Accessed March 9, 2026. https:\/\/grail.com\/press-releases\/landmark-nhs-galleri-trial-demonstrates-a-substantial-reduction-in-stage-iv-cancer-diagnoses-increased-stage-i-and-ii-detection-of-deadly-cancers-and-four-fold-higher-cancer-detection-rate\/"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2849767\/jama_mann_2026_oi_260038_1783020634.21917.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:00:27Z","timestamp":1784041227000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2849767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.6803","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}